Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.5 GBX | 0.00% | 0.00% | +18.27% |
03-19 | Tissue Regenix annual loss narrows sharply as revenue jumps | AN |
03-19 | Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -96% by 2026.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.27% | 54.35M | - | ||
+5.70% | 32.88B | C | ||
+18.46% | 7.84B | C- | ||
+22.71% | 3.95B | B- | ||
-17.95% | 3.11B | C- | ||
-19.93% | 1.38B | B | ||
-30.65% | 1.21B | - | ||
+4.36% | 933M | C | ||
-34.81% | 911M | - | ||
-26.60% | 829M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TRX Stock
- Ratings Tissue Regenix Group plc